FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ACSL5-TCF7L2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ACSL5-TCF7L2
FusionPDB ID: 1517
FusionGDB2.0 ID: 1517
HgeneTgene
Gene symbol

ACSL5

TCF7L2

Gene ID

51703

6934

Gene nameacyl-CoA synthetase long chain family member 5transcription factor 7 like 2
SynonymsACS2|ACS5|FACL5TCF-4|TCF4
Cytomap

10q25.2

10q25.2-q25.3

Type of geneprotein-codingprotein-coding
Descriptionlong-chain-fatty-acid--CoA ligase 5FACL5 for fatty acid coenzyme A ligase 5LACS 5arachidonate--CoA ligasefatty acid coenzyme A ligase 5fatty-acid-Coenzyme A ligase, long-chain 5long-chain acyl-CoA synthetase 5long-chain fatty acid coenzyme A ligasetranscription factor 7-like 2HMG box transcription factor 4T-cell factor 4T-cell-specific transcription factor 4hTCF-4transcription factor 7-like 2 (T-cell specific, HMG-box)
Modification date2020031320200315
UniProtAcc

Q9ULC5

Main function of 5'-partner protein: FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation (PubMed:17681178, PubMed:24269233, PubMed:22633490). ACSL5 may activate fatty acids from exogenous sources for the synthesis of triacylglycerol destined for intracellular storage (By similarity). Utilizes a wide range of saturated fatty acids with a preference for C16-C18 unsaturated fatty acids (By similarity). It was suggested that it may also stimulate fatty acid oxidation (By similarity). At the villus tip of the crypt-villus axis of the small intestine may sensitize epithelial cells to apoptosis specifically triggered by the death ligand TRAIL. May have a role in the survival of glioma cells. {ECO:0000250, ECO:0000269|PubMed:17681178, ECO:0000269|PubMed:18806831, ECO:0000269|PubMed:19459852, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233}.

Q9NQB0

Main function of 5'-partner protein: FUNCTION: Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine. {ECO:0000269|PubMed:12408868, ECO:0000269|PubMed:12727872, ECO:0000269|PubMed:19443654, ECO:0000269|PubMed:22699938, ECO:0000269|PubMed:9727977}.
Ensembl transtripts involved in fusion geneENST idsENST00000479936, ENST00000354273, 
ENST00000354655, ENST00000356116, 
ENST00000393081, ENST00000433418, 
ENST00000369410, 		ENST00000355995, 
ENST00000534894, ENST00000536810, 
ENST00000543371, ENST00000545257, 
ENST00000349937, ENST00000352065, 
ENST00000355717, ENST00000369386, 
ENST00000369389, ENST00000369395, 
ENST00000369397, ENST00000466338, 
ENST00000538897, ENST00000542695, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 6 X 5=18012 X 11 X 10=1320
# samples 617
** MAII scorelog2(6/180*10)=-1.58496250072116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(17/1320*10)=-2.95693127810811
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ACSL5 [Title/Abstract] AND TCF7L2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ACSL5 [Title/Abstract] AND TCF7L2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ACSL5(114154860)-TCF7L2(114724315), # samples:1
Anticipated loss of major functional domain due to fusion event.ACSL5-TCF7L2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ACSL5-TCF7L2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ACSL5-TCF7L2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ACSL5-TCF7L2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneACSL5

GO:0001676

long-chain fatty acid metabolic process

24269233

TgeneTCF7L2

GO:0000122

negative regulation of transcription by RNA polymerase II

12799378

TgeneTCF7L2

GO:0006357

regulation of transcription by RNA polymerase II

9727977

TgeneTCF7L2

GO:0032092

positive regulation of protein binding

12799378

TgeneTCF7L2

GO:0032350

regulation of hormone metabolic process

15525634

TgeneTCF7L2

GO:0042593

glucose homeostasis

15525634

TgeneTCF7L2

GO:0043433

negative regulation of DNA-binding transcription factor activity

12799378

TgeneTCF7L2

GO:0045444

fat cell differentiation

10937998

TgeneTCF7L2

GO:0045892

negative regulation of transcription, DNA-templated

12799378|15525634

TgeneTCF7L2

GO:0045944

positive regulation of transcription by RNA polymerase II

9065401|19168596

TgeneTCF7L2

GO:0048625

myoblast fate commitment

10937998



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:114154860/chr10:114724315)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ACSL5 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across TCF7L2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000354655ACSL5chr10114154860+ENST00000534894TCF7L2chr10114724315+15414372541540429
ENST00000354655ACSL5chr10114154860+ENST00000536810TCF7L2chr10114724315+35714372541864536
ENST00000354655ACSL5chr10114154860+ENST00000545257TCF7L2chr10114724315+36224372541915553
ENST00000354655ACSL5chr10114154860+ENST00000355995TCF7L2chr10114724315+36224372541915553
ENST00000354655ACSL5chr10114154860+ENST00000543371TCF7L2chr10114724315+35714372541864536
ENST00000393081ACSL5chr10114154860+ENST00000534894TCF7L2chr10114724315+15674632801566429
ENST00000393081ACSL5chr10114154860+ENST00000536810TCF7L2chr10114724315+35974632801890536
ENST00000393081ACSL5chr10114154860+ENST00000545257TCF7L2chr10114724315+36484632801941553
ENST00000393081ACSL5chr10114154860+ENST00000355995TCF7L2chr10114724315+36484632801941553
ENST00000393081ACSL5chr10114154860+ENST00000543371TCF7L2chr10114724315+35974632801890536
ENST00000433418ACSL5chr10114154860+ENST00000534894TCF7L2chr10114724315+1540436491539497
ENST00000433418ACSL5chr10114154860+ENST00000536810TCF7L2chr10114724315+3570436491863604
ENST00000433418ACSL5chr10114154860+ENST00000545257TCF7L2chr10114724315+3621436491914621
ENST00000433418ACSL5chr10114154860+ENST00000355995TCF7L2chr10114724315+3621436491914621
ENST00000433418ACSL5chr10114154860+ENST00000543371TCF7L2chr10114724315+3570436491863604
ENST00000356116ACSL5chr10114154860+ENST00000534894TCF7L2chr10114724315+1540436491539497
ENST00000356116ACSL5chr10114154860+ENST00000536810TCF7L2chr10114724315+3570436491863604
ENST00000356116ACSL5chr10114154860+ENST00000545257TCF7L2chr10114724315+3621436491914621
ENST00000356116ACSL5chr10114154860+ENST00000355995TCF7L2chr10114724315+3621436491914621
ENST00000356116ACSL5chr10114154860+ENST00000543371TCF7L2chr10114724315+3570436491863604
ENST00000354273ACSL5chr10114154860+ENST00000534894TCF7L2chr10114724315+1539435481538496
ENST00000354273ACSL5chr10114154860+ENST00000536810TCF7L2chr10114724315+3569435481862604
ENST00000354273ACSL5chr10114154860+ENST00000545257TCF7L2chr10114724315+3620435481913621
ENST00000354273ACSL5chr10114154860+ENST00000355995TCF7L2chr10114724315+3620435481913621
ENST00000354273ACSL5chr10114154860+ENST00000543371TCF7L2chr10114724315+3569435481862604

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000354655ENST00000534894ACSL5chr10114154860+TCF7L2chr10114724315+0.0096948530.9903052
ENST00000354655ENST00000536810ACSL5chr10114154860+TCF7L2chr10114724315+0.000861840.9991381
ENST00000354655ENST00000545257ACSL5chr10114154860+TCF7L2chr10114724315+0.0011863190.99881375
ENST00000354655ENST00000355995ACSL5chr10114154860+TCF7L2chr10114724315+0.0011974260.99880254
ENST00000354655ENST00000543371ACSL5chr10114154860+TCF7L2chr10114724315+0.0008622870.99913764
ENST00000393081ENST00000534894ACSL5chr10114154860+TCF7L2chr10114724315+0.0163475350.9836525
ENST00000393081ENST00000536810ACSL5chr10114154860+TCF7L2chr10114724315+0.0013983480.9986016
ENST00000393081ENST00000545257ACSL5chr10114154860+TCF7L2chr10114724315+0.0018423060.9981577
ENST00000393081ENST00000355995ACSL5chr10114154860+TCF7L2chr10114724315+0.0018681710.9981318
ENST00000393081ENST00000543371ACSL5chr10114154860+TCF7L2chr10114724315+0.0013655550.9986344
ENST00000433418ENST00000534894ACSL5chr10114154860+TCF7L2chr10114724315+0.0297032560.9702967
ENST00000433418ENST00000536810ACSL5chr10114154860+TCF7L2chr10114724315+0.0017461290.9982539
ENST00000433418ENST00000545257ACSL5chr10114154860+TCF7L2chr10114724315+0.0019577080.9980422
ENST00000433418ENST00000355995ACSL5chr10114154860+TCF7L2chr10114724315+0.0020946940.9979054
ENST00000433418ENST00000543371ACSL5chr10114154860+TCF7L2chr10114724315+0.0017548670.9982451
ENST00000356116ENST00000534894ACSL5chr10114154860+TCF7L2chr10114724315+0.0297032560.9702967
ENST00000356116ENST00000536810ACSL5chr10114154860+TCF7L2chr10114724315+0.0017461290.9982539
ENST00000356116ENST00000545257ACSL5chr10114154860+TCF7L2chr10114724315+0.0019577080.9980422
ENST00000356116ENST00000355995ACSL5chr10114154860+TCF7L2chr10114724315+0.0020946940.9979054
ENST00000356116ENST00000543371ACSL5chr10114154860+TCF7L2chr10114724315+0.0017548670.9982451
ENST00000354273ENST00000534894ACSL5chr10114154860+TCF7L2chr10114724315+0.0299060120.97009397
ENST00000354273ENST00000536810ACSL5chr10114154860+TCF7L2chr10114724315+0.00176760.9982324
ENST00000354273ENST00000545257ACSL5chr10114154860+TCF7L2chr10114724315+0.0019858150.9980142
ENST00000354273ENST00000355995ACSL5chr10114154860+TCF7L2chr10114724315+0.0021192260.9978808
ENST00000354273ENST00000543371ACSL5chr10114154860+TCF7L2chr10114724315+0.0017771810.99822277

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ACSL5-TCF7L2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ACSL5chr10114154860TCF7L2chr10114724315435129PLLDLNNQSVGIELHFQSGSTHYSAY
ACSL5chr10114154860TCF7L2chr10114724315436129PLLDLNNQSVGIELHFQSGSTHYSAY
ACSL5chr10114154860TCF7L2chr1011472431543761PLLDLNNQSVGIELHFQSGSTHYSAY
ACSL5chr10114154860TCF7L2chr1011472431546361PLLDLNNQSVGIELHFQSGSTHYSAY

Top

Potential FusionNeoAntigen Information of ACSL5-TCF7L2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ACSL5-TCF7L2_114154860_114724315.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B39:01NQSVGIEL0.9810.9234614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B39:13NQSVGIEL0.92150.9331614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:37NQSVGIEL0.90.5236614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B57:01QSVGIELHF0.99680.9799716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:17QSVGIELHF0.99680.8712716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:16QSVGIELHF0.99590.8074716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B58:02QSVGIELHF0.99370.9751716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B58:01QSVGIELHF0.99340.9667716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B57:03QSVGIELHF0.98240.9779716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-A32:13QSVGIELHF0.60870.9715716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B13:01QSVGIELHF0.15010.9417716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B13:01NQSVGIELHF0.88710.8573616
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:18ELHFQSGSTH0.51110.81451222
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:02ELHFQSGSTHY0.98870.93831223
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:18IELHFQSGSTH0.88780.77481122
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B39:08NQSVGIEL0.97010.8286614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B39:05NQSVGIEL0.89440.9112614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B14:03NQSVGIEL0.88850.8114614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-C15:04QSVGIELHF0.99560.9404716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-C03:14QSVGIELHF0.90740.9892716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B14:03NNQSVGIEL0.63440.8234514
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B39:02NQSVGIEL0.9840.936614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B39:31NQSVGIEL0.97860.922614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B39:11NQSVGIEL0.950.7849614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:09NQSVGIEL0.84810.6816614
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-C03:02QSVGIELHF0.99810.9687716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B57:04QSVGIELHF0.9970.8673716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B57:10QSVGIELHF0.99680.9799716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B58:06QSVGIELHF0.99610.9146716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-C15:09QSVGIELHF0.99560.9404716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:13QSVGIELHF0.9920.7818716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B57:02QSVGIELHF0.9910.9768716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:24QSVGIELHF0.98740.8483716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B35:28QSVGIELHF0.96690.949716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B39:11NNQSVGIEL0.94430.7495514
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-A32:01QSVGIELHF0.91610.9547716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-C16:02QSVGIELHF0.66760.994716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-C02:02QSVGIELHF0.12970.9787716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-C02:10QSVGIELHF0.12970.9787716
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:12NQSVGIELHF0.99490.8442616
ACSL5-TCF7L2chr10114154860chr10114724315435HLA-B15:12ELHFQSGSTHY0.99820.93291223

Top

Potential FusionNeoAntigen Information of ACSL5-TCF7L2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of ACSL5-TCF7L2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6343NQSVGIELHFQSGSACSL5TCF7L2chr10114154860chr10114724315435

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ACSL5-TCF7L2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6343NQSVGIELHFQSGS-7.9962-8.1096
HLA-B14:023BVN6343NQSVGIELHFQSGS-5.70842-6.74372
HLA-B52:013W396343NQSVGIELHFQSGS-6.83737-6.95077
HLA-B52:013W396343NQSVGIELHFQSGS-4.4836-5.5189
HLA-A11:014UQ26343NQSVGIELHFQSGS-10.0067-10.1201
HLA-A11:014UQ26343NQSVGIELHFQSGS-9.03915-10.0745
HLA-A24:025HGA6343NQSVGIELHFQSGS-6.56204-6.67544
HLA-A24:025HGA6343NQSVGIELHFQSGS-5.42271-6.45801
HLA-B44:053DX86343NQSVGIELHFQSGS-7.85648-8.89178
HLA-B44:053DX86343NQSVGIELHFQSGS-5.3978-5.5112
HLA-A02:016TDR6343NQSVGIELHFQSGS-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ACSL5-TCF7L2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ACSL5-TCF7L2chr10114154860chr101147243151122IELHFQSGSTHATTGAGCTCCATTTTCAGTCCGGCAGCACACAT
ACSL5-TCF7L2chr10114154860chr101147243151222ELHFQSGSTHGAGCTCCATTTTCAGTCCGGCAGCACACAT
ACSL5-TCF7L2chr10114154860chr101147243151223ELHFQSGSTHYGAGCTCCATTTTCAGTCCGGCAGCACACATTAC
ACSL5-TCF7L2chr10114154860chr10114724315514NNQSVGIELAACAATCAGTCTGTGGGAATTGAGCTC
ACSL5-TCF7L2chr10114154860chr10114724315614NQSVGIELAATCAGTCTGTGGGAATTGAGCTC
ACSL5-TCF7L2chr10114154860chr10114724315616NQSVGIELHFAATCAGTCTGTGGGAATTGAGCTCCATTTT
ACSL5-TCF7L2chr10114154860chr10114724315716QSVGIELHFCAGTCTGTGGGAATTGAGCTCCATTTT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of ACSL5-TCF7L2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
READACSL5-TCF7L2chr10114154860ENST00000354273chr10114724315ENST00000355995TCGA-AG-4007

Top

Potential target of CAR-T therapy development for ACSL5-TCF7L2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneACSL5chr10:114154860chr10:114724315ENST00000354273+22112_3252684.0TransmembraneHelical%3B Signal-anchor for type III membrane protein
HgeneACSL5chr10:114154860chr10:114724315ENST00000354655+22112_3252684.0TransmembraneHelical%3B Signal-anchor for type III membrane protein
HgeneACSL5chr10:114154860chr10:114724315ENST00000356116+22112_32108740.0TransmembraneHelical%3B Signal-anchor for type III membrane protein
HgeneACSL5chr10:114154860chr10:114724315ENST00000393081+22112_3252684.0TransmembraneHelical%3B Signal-anchor for type III membrane protein
HgeneACSL5chr10:114154860chr10:114724315ENST00000433418+22012_3252660.0TransmembraneHelical%3B Signal-anchor for type III membrane protein

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ACSL5-TCF7L2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ACSL5-TCF7L2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneACSL5C0003865Arthritis, Adjuvant-Induced1CTD_human
HgeneACSL5C0971858Arthritis, Collagen-Induced1CTD_human
HgeneACSL5C0993582Arthritis, Experimental1CTD_human
TgeneTCF7L2C0036341Schizophrenia4PSYGENET
TgeneTCF7L2C0011860Diabetes Mellitus, Non-Insulin-Dependent3CTD_human
TgeneTCF7L2C0009402Colorectal Carcinoma2CTD_human;UNIPROT
TgeneTCF7L2C0009404Colorectal Neoplasms2CTD_human
TgeneTCF7L2C0001418Adenocarcinoma1CTD_human
TgeneTCF7L2C0005586Bipolar Disorder1PSYGENET
TgeneTCF7L2C0007102Malignant tumor of colon1CTD_human
TgeneTCF7L2C0007193Cardiomyopathy, Dilated1CTD_human
TgeneTCF7L2C0009375Colonic Neoplasms1CTD_human
TgeneTCF7L2C0010068Coronary heart disease1CTD_human
TgeneTCF7L2C0020507Hyperplasia1CTD_human
TgeneTCF7L2C0036337Schizoaffective Disorder1PSYGENET
TgeneTCF7L2C0087031Juvenile-Onset Still Disease1CTD_human
TgeneTCF7L2C0151744Myocardial Ischemia1CTD_human
TgeneTCF7L2C0205641Adenocarcinoma, Basal Cell1CTD_human
TgeneTCF7L2C0205642Adenocarcinoma, Oxyphilic1CTD_human
TgeneTCF7L2C0205643Carcinoma, Cribriform1CTD_human
TgeneTCF7L2C0205644Carcinoma, Granular Cell1CTD_human
TgeneTCF7L2C0205645Adenocarcinoma, Tubular1CTD_human
TgeneTCF7L2C0600519Ventricular Remodeling1CTD_human
TgeneTCF7L2C0600520Left Ventricle Remodeling1CTD_human
TgeneTCF7L2C1449563Cardiomyopathy, Familial Idiopathic1CTD_human
TgeneTCF7L2C1535926Neurodevelopmental Disorders1CTD_human
TgeneTCF7L2C2931456Prostate cancer, familial1CTD_human
TgeneTCF7L2C3495559Juvenile arthritis1CTD_human
TgeneTCF7L2C3714758Juvenile psoriatic arthritis1CTD_human
TgeneTCF7L2C4552091Polyarthritis, Juvenile, Rheumatoid Factor Negative1CTD_human
TgeneTCF7L2C4704862Polyarthritis, Juvenile, Rheumatoid Factor Positive1CTD_human
TgeneTCF7L2C4722327PROSTATE CANCER, HEREDITARY, 11CTD_human